These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 32397769)

  • 1. Upregulation of TIGIT and PD-1 in Colorectal Cancer with Mismatch-repair Deficiency.
    Zhou X; Ding X; Li H; Yang C; Ma Z; Xu G; Yang S; Zhang D; Xie X; Xin L; Luo X
    Immunol Invest; 2021 May; 50(4):338-355. PubMed ID: 32397769
    [No Abstract]   [Full Text] [Related]  

  • 2. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.
    Le DT; Durham JN; Smith KN; Wang H; Bartlett BR; Aulakh LK; Lu S; Kemberling H; Wilt C; Luber BS; Wong F; Azad NS; Rucki AA; Laheru D; Donehower R; Zaheer A; Fisher GA; Crocenzi TS; Lee JJ; Greten TF; Duffy AG; Ciombor KK; Eyring AD; Lam BH; Joe A; Kang SP; Holdhoff M; Danilova L; Cope L; Meyer C; Zhou S; Goldberg RM; Armstrong DK; Bever KM; Fader AN; Taube J; Housseau F; Spetzler D; Xiao N; Pardoll DM; Papadopoulos N; Kinzler KW; Eshleman JR; Vogelstein B; Anders RA; Diaz LA
    Science; 2017 Jul; 357(6349):409-413. PubMed ID: 28596308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. T cell-inflamed phenotype and increased Foxp3 expression in infiltrating T-cells of mismatch-repair deficient endometrial cancers.
    Asaka S; Yen TT; Wang TL; Shih IM; Gaillard S
    Mod Pathol; 2019 Apr; 32(4):576-584. PubMed ID: 30401949
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of immune checkpoints and T cell exhaustion markers in early and advanced stages of colorectal cancer.
    Saleh R; Taha RZ; Toor SM; Sasidharan Nair V; Murshed K; Khawar M; Al-Dhaheri M; Petkar MA; Abu Nada M; Elkord E
    Cancer Immunol Immunother; 2020 Oct; 69(10):1989-1999. PubMed ID: 32393998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mismatch repair deficiency is associated with MSI phenotype, increased tumor-infiltrating lymphocytes and PD-L1 expression in immune cells in ovarian cancer.
    Xiao X; Dong D; He W; Song L; Wang Q; Yue J; Xie L
    Gynecol Oncol; 2018 Apr; 149(1):146-154. PubMed ID: 29496294
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation of T Cell Immunoglobulin and ITIM Domain (TIGIT) and Programmed Death 1 (PD-1) with Clinicopathological Characteristics of Renal Cell Carcinoma May Indicate Potential Targets for Treatment.
    Hong X; Wang X; Wang T; Zhang X
    Med Sci Monit; 2018 Sep; 24():6861-6872. PubMed ID: 30262800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic impact of programed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor infiltrating lymphocytes in colorectal cancer.
    Li Y; Liang L; Dai W; Cai G; Xu Y; Li X; Li Q; Cai S
    Mol Cancer; 2016 Aug; 15(1):55. PubMed ID: 27552968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. T-cell immunoglobulin and ITIM domain, as a potential immune checkpoint target for immunotherapy of colorectal cancer.
    Fathi M; Pustokhina I; Kuznetsov SV; Khayrullin M; Hojjat-Farsangi M; Karpisheh V; Jalili A; Jadidi-Niaragh F
    IUBMB Life; 2021 May; 73(5):726-738. PubMed ID: 33686787
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TIGIT presents earlier expression dynamic than PD-1 in activated CD8
    Hu F; Wang W; Fang C; Bai C
    Exp Cell Res; 2020 Nov; 396(1):112260. PubMed ID: 32890458
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blimp-1 impairs T cell function via upregulation of TIGIT and PD-1 in patients with acute myeloid leukemia.
    Zhu L; Kong Y; Zhang J; Claxton DF; Ehmann WC; Rybka WB; Palmisiano ND; Wang M; Jia B; Bayerl M; Schell TD; Hohl RJ; Zeng H; Zheng H
    J Hematol Oncol; 2017 Jun; 10(1):124. PubMed ID: 28629373
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of lymphocyte-activating gene 3 and T-cell immunoreceptor with immunoglobulin and ITIM domains in cutaneous melanoma and their correlation with programmed cell death 1 expression in tumor-infiltrating lymphocytes.
    Lee WJ; Lee YJ; Choi ME; Yun KA; Won CH; Lee MW; Choi JH; Chang SE
    J Am Acad Dermatol; 2019 Jul; 81(1):219-227. PubMed ID: 30880064
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Systematic Review and Meta-Analysis on the Significance of TIGIT in Solid Cancers: Dual TIGIT/PD-1 Blockade to Overcome Immune-Resistance in Solid Cancers.
    Hosseinkhani N; Shadbad MA; Asghari Jafarabadi M; Karim Ahangar N; Asadzadeh Z; Mohammadi SM; Lotfinejad P; Alizadeh N; Brunetti O; Fasano R; Silvestris N; Baradaran B
    Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638729
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TIGIT and PD-1 impair tumor antigen-specific CD8⁺ T cells in melanoma patients.
    Chauvin JM; Pagliano O; Fourcade J; Sun Z; Wang H; Sander C; Kirkwood JM; Chen TH; Maurer M; Korman AJ; Zarour HM
    J Clin Invest; 2015 May; 125(5):2046-58. PubMed ID: 25866972
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differences in the immunosurveillance pattern associated with DNA mismatch repair status between right-sided and left-sided colorectal cancer.
    Kanno H; Miyoshi H; Yoshida N; Sudo T; Nakashima K; Takeuchi M; Nomura Y; Seto M; Hisaka T; Tanaka H; Okuda K; Akagi Y; Ohshima K
    Cancer Sci; 2020 Aug; 111(8):3032-3044. PubMed ID: 32449240
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TIGIT and PD-1 may serve as potential prognostic biomarkers for gastric cancer.
    Xu D; Zhao E; Zhu C; Zhao W; Wang C; Zhang Z; Zhao G
    Immunobiology; 2020 May; 225(3):151915. PubMed ID: 32122675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy holds the key to cancer treatment and prevention in constitutional mismatch repair deficiency (CMMRD) syndrome.
    Westdorp H; Kolders S; Hoogerbrugge N; de Vries IJM; Jongmans MCJ; Schreibelt G
    Cancer Lett; 2017 Sep; 403():159-164. PubMed ID: 28645564
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TIGIT Expression Is Associated with T-cell Suppression and Exhaustion and Predicts Clinical Outcome and Anti-PD-1 Response in Follicular Lymphoma.
    Yang ZZ; Kim HJ; Wu H; Jalali S; Tang X; Krull JE; Ding W; Novak AJ; Ansell SM
    Clin Cancer Res; 2020 Oct; 26(19):5217-5231. PubMed ID: 32631956
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TIGIT expression is upregulated in T cells and causes T cell dysfunction independent of PD-1 and Tim-3 in adult B lineage acute lymphoblastic leukemia.
    Zhang X; Zhang H; Chen L; Feng Z; Gao L; Li Q
    Cell Immunol; 2019 Oct; 344():103958. PubMed ID: 31376919
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mismatch repair-deficient colorectal cancer: a model of immunogenic and immune cell-rich tumor despite nonsignificant programmed cell death ligand-1 expression in tumor cells.
    Le Flahec G; Badic B; Guibourg B; Doucet L; Bail JP; Marcorelles P; Schick U; Uguen A
    Hum Pathol; 2018 Feb; 72():135-143. PubMed ID: 29208565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PD-L1 Expression in Mismatch Repair-deficient Endometrial Carcinomas, Including Lynch Syndrome-associated and MLH1 Promoter Hypermethylated Tumors.
    Sloan EA; Ring KL; Willis BC; Modesitt SC; Mills AM
    Am J Surg Pathol; 2017 Mar; 41(3):326-333. PubMed ID: 27984238
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.